Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD

Giovanni Targher, Alessandro Mantovani, Anna Alisi, Antonella Mosca, Nadia Panera, Christopher D. Byrne, Valerio Nobili – 26 March 2019 – Emerging evidence suggests that patatin‐like phospholipase domain–containing protein‐3 (PNPLA3) rs738409 genotype (the major genetic variant associated with susceptibility to nonalcoholic fatty liver disease [NAFLD]) is associated with decreased kidney function in adults. Currently, it is uncertain whether this association also occurs in children/adolescents and whether any association is independent of liver disease severity.

Clinical Implications of Donor Warm and Cold Ischemia Time in Donor After Circulatory Death Liver Transplantation

Flavio Paterno, James V. Guarrera, Koffi Wima, Tayyab Diwan, Madison C. Cuffy, Nadeem Anwar, E. Steve Woodle, Shimul Shah – 26 March 2019 – The use of donation after circulatory death (DCD) liver allografts has been constrained by limitations in the duration of donor warm ischemia time (DWIT), donor agonal time (DAT), and cold ischemia time (CIT). The purpose of this study is to assess the impact of longer DWIT, DAT, and CIT on graft survival and other outcomes in DCD liver transplants.

The Effects of Liver Transplantation in Children With Niemann‐Pick Disease Type B

Yuan Liu, Yi Luo, Lei Xia, Bijun Qiu, Tao Zhou, Mingxuan Feng, Feng Xue, Xiaosong Chen, Longzhi Han, Jianjun Zhang, Qiang Xia – 26 March 2019 – We evaluated the effects of liver transplantation (LT) in children with Niemann‐Pick disease (NPD) type B. From October 2006 to October 2018, 7 of 1512 children who received LT at Ren Ji Hospital were diagnosed as NPD type B. The median age at diagnosis was 12 months (6‐14 months) with initial presentations of hepatosplenomegaly, growth retardation, repeated pneumonia, and diarrhea.

Expanding and Underscoring the Hepato‐Encephalopathic Phenotype of QIL1/MIC13

Bianca E. Russell, Kaitlin G. Whaley, Kevin E. Bove, Anatalia Labilloy, Rachel C. Lombardo, Robert J. Hopkin, Nancy D. Leslie, Carlos Prada, Zahra Assouline, Giulia Barcia, Juliette Bouchereau, Maryline Chomton, Dominique Debray, Imen Dorboz, Philippe Durand, Pauline Gaignard, Dalila Habes, Claude Jardel, François Labarthe, Jonathan Lévy, Anne Lombès, Claire Mehler‐Jacob, Judith Melki, Laura Menvielle, Arnold Munnich, Charlotte Mussini, Samia Pichard, Marlène Rio, Agnès Rötig, Samira Sissaoui, Abdelhamid Slama, Alexander G Miethke, Manuel Schiff – 26 March 2019

Patients With Acute on Chronic Liver Failure Grade 3 Have Greater 14‐Day Waitlist Mortality Than Status‐1a Patients

Vinay Sundaram, Parth Shah, Robert J. Wong, Constantine J. Karvellas, Brett E. Fortune, Nadim Mahmud, Alexander Kuo, Rajiv Jalan – 25 March 2019 – Patients listed for liver transplantation (LT) as status 1a currently receive the highest priority on the waiting list. The presence of acute on chronic liver failure (ACLF) with three or more organs failing (ACLF‐3) portends low survival without transplantation, which may not be reflected by the Model for End‐Stage Liver Disease‐Sodium (MELD‐Na) score.

Impact of Chronic Kidney Disease on Outcomes in Cirrhosis

Florence Wong, K. Rajender Reddy, Jacqueline G. O’Leary, Puneeta Tandon, Scott W. Biggins, Guadalupe Garcia‐Tsao, Benedict J. Maliakkal, Jennifer C. Lai, Michael B. Fallon, Hugo E. Vargas, Ram Subramanian, Paul J. Thuluvath, Patrick S. Kamath, Leroy Thacker, Jasmohan S. Bajaj – 25 March 2019 – We hypothesize that the prevalence of chronic kidney disease (CKD) among patients with cirrhosis has increased due to the increased prevalence of CKD‐associated comorbidities, such as diabetes.

Telemedicine: An Evolving Field in Hepatology

Cindy Piao, Norah A. Terrault, Souvik Sarkar – 25 March 2019 – Healthcare delivery has been dramatically changing in recent times with advances in technology. One area of expansion has been the use of telemedicine due to progression in communication technologies. Telemedicine offers the opportunity to overcome barriers of access, improve patient satisfaction, improve healthcare outcomes and streamline communication between patients and providers.

Lipocalin‐2 Protects Against Diet‐Induced Nonalcoholic Fatty Liver Disease by Targeting Hepatocytes

Yanyong Xu, Yingdong Zhu, Kavita Jadhav, Yuanyuan Li, Huihui Sun, Liya Yin, Takhar Kasumov, Xiaoli Chen, Yanqiao Zhang – 25 March 2019 – Hepatocytes are the major source of hepatic lipocalin‐2 (LCN2), which is up‐regulated in response to inflammation, injury, or metabolic stress. So far, the role of hepatocyte‐derived LCN2 in the development of nonalcoholic fatty liver disease (NAFLD) remains unknown.

Subscribe to